Skip to main content

News

All the latest news and information on the main advances in research, institutional milestones, teaching and management. Find out what happens at the Vall d'Hebron Research Institute!

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

The results show that tobacco affects the expression of some genes related to the development of this type of headache.

Aquests guardons reconeixen els millors serveis i unitats de l’Estat, tant públics com privats, que busquen l’excel•lència en l’atenció que presten als seus pacients.

La 4º jornada del maneig integral del dolor busca agilitzar la transferència d’estudis preclínics a l’assistència per millorar la qualitat de vida dels pacients

Entre els projectes més rellevants en Covid-19 destaca la participació del VHIR en assaigs clínics per provar l’eficàcia i seguretat de vacunes com ara Janssen, Pfizer-BioNTech en el col·lectiu d’embarassades, i Hipra.

When post-COVID-19 headache lasts for a month, there is a 50% change of it continuing for the next nine months.

The results show that there are two types of migraine attacks depending on whether CGRP levels increase or not during the acute phase.